Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Waldenström's macroglobulinemia.

Jennifer A McKenna1

  • 1jmckenn2@caregroup.harvard.edu

Clinical Journal of Oncology Nursing
|September 21, 2002
PubMed
Summary

Waldenström's macroglobulinemia (WM) is a rare cancer. Treatments for symptomatic WM include chemotherapy and newer targeted therapies, improving patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.

PloS one·2014
Same author

Water VBAC: exploring a new frontier for women's autonomy.

Midwifery·2013
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Waldenström's macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma and a type of monoclonal gammopathy.
  • Clinical manifestations include fatigue, lymphadenopathy, hepatosplenomegaly, and neuropathy.
  • A hallmark of WM is the presence of monoclonal immunoglobulin M (IgM) protein, which can lead to hyperviscosity syndrome.

Purpose of the Study:

  • To provide an overview of Waldenström's macroglobulinemia.
  • To discuss the clinical presentation and diagnostic markers.
  • To outline current and emerging treatment strategies for WM.

Main Methods:

  • Literature review of Waldenström's macroglobulinemia.
  • Summary of clinical signs, symptoms, and diagnostic findings.
  • Overview of therapeutic approaches, including chemotherapy and targeted therapy.

Main Results:

  • WM presents with a range of symptoms, often related to lymphoproliferation and high IgM levels.
  • Hyperviscosity syndrome is a significant complication of elevated IgM.
  • Treatment options vary based on symptom severity and disease status.

Conclusions:

  • Effective management of WM requires understanding its pathophysiology and clinical spectrum.
  • Treatment strategies are evolving, with newer agents offering improved outcomes.
  • Oncology nurses play a crucial role in patient education and care for WM patients.

Related Experiment Videos